Millions of women who missed early HPV vaccination opportunities now face rising cervical cancer rates. New research shows screening rates dropping precisely when they're needed most.

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.